BAXTER Company Profile

What is the competitive landscape for BAXTER

BAXTER has two hundred and twenty-one approved drugs.

There are twenty-five US patents protecting BAXTER drugs. There are three tentative approvals on BAXTER drugs.

There are forty-nine patent family members on BAXTER drugs in nineteen countries and three hundred and thirty-eight supplementary protection certificates in seventeen countries.

Summary for BAXTER

International Patents:	49
US Patents:	25
Tradenames:	305
Ingredients:	134
NDAs:	221
Patent Litigation for BAXTER:	See patent lawsuits for BAXTER
PTAB Cases with BAXTER as patent owner:	See PTAB cases with BAXTER as patent owner

Drugs and US Patents for BAXTER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER	sodium lactate	INJECTABLE;INJECTION	016692-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Baxter Hlthcare	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)	dextrose; potassium chloride; sodium chloride	INJECTABLE;INJECTION	018037-004	Approved Prior to Jan 1, 1982	AP	RX	No	No
Baxter Hlthcare	DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER	dobutamine hydrochloride	INJECTABLE;INJECTION	020255-003	Oct 19, 1993	AP	RX	Yes	Yes
Baxter Hlthcare	TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER	amino acids; dextrose; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	020147-002	Oct 23, 1995		DISCN	No	No

Expired US Patents for BAXTER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988	3,732,340
Baxter Hlthcare	NEXTERONE	amiodarone hydrochloride	INJECTABLE;INJECTION	022325-001	Dec 24, 2008	5,134,127
Baxter Hlthcare Corp	CLINOLIPID 20%	olive oil; soybean oil	EMULSION;INTRAVENOUS	204508-001	Oct 3, 2013	5,840,757
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-004	Oct 10, 1992	4,220,660

Paragraph IV (Patent) Challenges for BAXTER drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags		2014-01-31
	Inhalation	99.90%		2008-09-11

International Patents for BAXTER Drugs

Country	Patent Number	Estimated Expiration
Mexico	375873
Eurasian Patent Organization	031355
Israel	208956
Israel	243654

Supplementary Protection Certificates for BAXTER Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1856135	CA 2020 00018	Denmark		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
0788360	04C0014	France		PRODUCT NAME: BORTEZOMIB; REGISTRATION NO/DATE: EU/1/04/274/001 20040426
1856135	CR 2020 00018	Denmark		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Baxter Hlthcare
• Baxter Hlthcare Corp